Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - erythromycin lactobionate, quantity: 1.49 g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin panpharma (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and skin structure infections caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment).,? diphtheria - as an adjunct to diphtheria antitoxin in infections due to corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers.,? acute pelvic inflammatory disease caused by neisseria gonorrhoeae: erythromycin panpharma (sterile erythromycin lactobionate) followed by erythromycin stearate, base or ethyl succinate orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin.,? before treatment of gonorrhoea, patients who are suspected of also having syphilis should have microscopic examination for t. pallidum (by immuno-fluorescence or dark field) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter.,? legionnaires' disease caused by legionella pneumophila. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease.

Spojené štáty - angličtina - NLM (National Library of Medicine)

versapharm incorporated - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 ml - erythromycin pledgets usp, 2% are indicated for the topical treatment of acne vulgaris. erythromycin pledgets usp, 2% are contraindicated in those individuals who have shown hypersensitivity to any of its components.

Spojené štáty - angličtina - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 g - erythromycin topical gel usp, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical gel usp, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Spojené štáty - angličtina - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 g - erythromycin topical gel usp, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical gel usp, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Spojené štáty - angličtina - NLM (National Library of Medicine)

renaissance pharma, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 g - erythromycin topical gel usp, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical gel usp, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Spojené štáty - angličtina - NLM (National Library of Medicine)

e. fougera & co. a division of fougera pharmaceuticals inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 g - erythromycin topical gel usp, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical gel usp, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - erythromycin lactobionate, quantity: 1.4882 g/g (equivalent: erythromycin, qty 1 g) - injection, powder for - excipient ingredients: - oral erythromycin is not considered to be the antibiotic of choice in severely ill patients.,erythromycin-link (sterile erythromycin lactobionate) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. intravenous therapy should be replaced by oral administration at the appropriate time.,? upper respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae); haemophilus influenzae (many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).,? lower respiratory tract infections caused by streptococcus pyogenes (group a beta-haemolytic streptococci); streptococcus pneumoniae (diplococcus pneumoniae).,? respiratory tract infections due to mycoplasma pneumoniae.,? skin and s

Keňa - angličtina - Pharmacy and Poisons Board

biodeal laboratories ltd p.o. box 32040 nairoki kenya - erythromycin ethyl succinate b.p. - powder for oral solution - erythromycin ethyl succinate b.p 125mg/5ml - antibacterials for systemic use: macrolides

Spojené štáty - angličtina - NLM (National Library of Medicine)

stat rx usa - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release capsules and other antibacterial drugs, erythromycin delayed-release capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the er

Spojené štáty - angličtina - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - erythromycin 30 mg in 1 g - erythromycin and benzoyl peroxide topical gel usp is indicated for the topical treatment of acne vulgaris. erythromycin and benzoyl peroxide topical gel usp is contraindicated in those individuals who have shown hypersensitivity to any of its components.